RecruitingPreclinical Alzheimer's Disease
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
Eligible age
55–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Sponsor: NewAmsterdam Pharma
You may qualify if…
- ✓ participants with preclinical AD
You may not qualify if…
- ✕ APOE genotype not meeting protocol-defined eligibility criteria
Where it's recruiting
Tennessee
Nashville
Source: ClinicalTrials.gov · NCT07794670 · last updated 2026-09-28